Hansa Biopharma Reports 46% Revenue Growth, FDA Submission for Imlifidase
Event summary
- Hansa Biopharma reported 46% revenue growth for IDEFIRIX in Europe, driven by expanded reimbursement across 24 countries.
- Positive Phase 3 trial results for imlifidase (p<0.0001) support potential U.S. launch after BLA submission in December 2025.
- Company raised $96M and restructured debt with NovaQuest to strengthen financial position.
- Strategic decision to advance HNSA-5487 for Guillain–Barré syndrome with planned FDA interactions in H1 2026.
- New leadership team appointed, including CEO Renée Aguiar-Lucander, to drive growth strategy.
The big picture
Hansa Biopharma's 2025 transformation under new leadership positions it for sustained growth, with key milestones in both clinical development and commercial expansion. The company's focus on addressing unmet needs in transplantation and autoimmune diseases aligns with broader industry trends toward precision therapies. Success hinges on regulatory approvals and execution of its expanded pipeline strategy.
What we're watching
- Regulatory Momentum
- Whether the FDA will approve imlifidase under the accelerated pathway and the timeline for potential U.S. launch.
- Commercial Execution
- How Hansa scales IDEFIRIX adoption beyond Europe, particularly in high-growth markets.
- Pipeline Progress
- The pace at which HNSA-5487 advances through development for Guillain–Barré syndrome.
Related topics